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AbstrACt
Introduction Although the new generation of cardiac 
troponin assays have revolutionised the diagnosis of 
myocardial infarction (MI), their application in triaging 
patients with suspected acute coronary syndrome 
requires further investigation. The objectives of the current 
systematic review are to evaluate the diagnostic accuracy 
of contemporary and high-sensitivity cardiac troponin 
assays used in serial testing, versus single-sample testing 
as a comparator, to identify patients with non-ST-segment-
elevation MI in the emergency department.
Methods and analysis We will conduct systematic 
searches of MEDLINE, EMBASE, Science Citation Index, 
the Cochrane Database of Systematic Reviews and the 
CENTRAL database covering the period from 1 January 2006 
to present, with no restrictions on language or publication 
status. Two review authors will independently screen studies 
for inclusion, extract data from eligible studies and assess 
their methodological quality using Quality Assessment 
of Diagnostic Accuracy Studies version 2. Studies will be 
included if they evaluate contemporary or high-sensitivity 
cardiac troponin assays used in serial testing, in patients 
presenting to the ED with suspicion of MI. Estimates of 
sensitivity and specificity from each study will be presented 
in forest plots and in the receiver-operating characteristics 
space. If appropriate, we will pool the results using Bayesian 
hierarchical models that allow correction for imperfect 
reference standard. We will obtain summary estimates of 
sensitivity and specificity of alternative testing protocols and 
compare their accuracy. We will also investigate the impact 
of prespecified sources of heterogeneity and methodological 
quality items. If pooling of results is considered inappropriate, 
we will present our findings in tables and diagrams and will 
describe them narratively.
Ethics and dissemination No formal ethical approval will 
be sought, but we will report on the ethical approval of the 
included studies. Dissemination of findings will be through 
publications in peer-reviewed journals, presentations at 
conferences and the websites of the universities.
PrOsPErO registration number CRD42018106379.
IntrOduCtIOn  
Coronary heart disease is one of the most 
common chronic conditions causing more 
than 7 million deaths worldwide each year.1 
The underlying pathogenesis is progressive 
accumulation of atheromatous plaque on 
the walls of the coronary arteries which, in its 
advanced stages, obstructs the normal blood 
flow and causes myocardial ischaemia. If the 
plaque gets ruptured, clots may form and 
limit, or completely cut-off, the blood supply 
to part of the heart muscle. This life-threat-
ening condition is known as ‘acute coronary 
syndrome’ and presents with chest pain, 
dyspnoea, nausea and other unspecific symp-
toms. It includes type 1 myocardial infarc-
tion (MI), if there is evidence of permanent 
damage to the heart muscle, or unstable 
angina, if no evidence of myocardial necrosis 
strengths and limitations of this study
 ► Systematic and comprehensive searches to identify 
all published and unpublished studies.
 ► Robust procedures for screening, data extraction 
and methodological quality assessment, based on 
prespecified criteria.
 ► Statistical methods for pooling results that allow 
correction for an imperfect reference standard.
 ► If the number of studies is too small and heterogene-
ity in study-level estimates is considered too great, 
we may not be able to obtain summary estimates of 
sensitivity and specificity.
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is detected.2 MI could also happen in the absence of 
acute coronary syndrome, as a result of other processes, 
including mismatch between myocardial oxygen supply 
and demand (type 2 MI).3 
Patients with MI require urgent specialist treatment and 
their outcomes depend on a timely and accurate diag-
nosis. However, diagnosis in an emergency setting could 
be challenging, as clinical symptoms lack sufficient sensi-
tivity and specificity4 and a normal ECG does not rule out 
the condition. Therefore, in patients suspected of MI but 
with non-diagnostic ECG, the current guidelines recom-
mend determination of troponin T or I, highly specific 
biomarkers of cardiac necrosis, both as a triage tool and 
in establishing the final diagnosis.5 6
Although cardiac troponins are specific to myocardial 
necrosis, they are not specific to MI, and elevated concen-
tration could be found in a number of other acute and 
chronic conditions that cause myocardial injury. The 
main difference between acute MI and most of the other 
conditions is the pattern of dynamic changes. Acute MI 
is characterised by a sharp increase in the bloodstream 
concentration of troponin in the first 24 hours of symptom 
onset, reflecting the progressive nature of the condi-
tion. Consequently, a significant difference in troponin 
concentrations from two consecutive samples (usually 
referred to as ‘delta troponin’) is interpreted as an indica-
tion that the underlying condition is most likely acute MI. 
Another consideration is the fact that in the first 2 hours 
of symptom onset, the level of cardiac troponin in the 
bloodstream may not exceed the 99th centile, which is an 
arbitrary cut-off used to dichotomise patients as having or 
not having myocardial injury. Therefore, a single determi-
nation early in the diagnostic process might miss patients 
with an evolving MI.
Contemporary and high-sensitivity cardiac troponin assays
Older generations of cardiac troponin assays lacked the 
precision and sensitivity to identify a small increase in 
the bloodstream level of the biomarker soon after onset 
of symptoms. Therefore, testing was done 6–12 hours 
after presentation to the ED, causing considerable delay 
in diagnosis and treatment, and unnecessary hospital 
admissions of patients without MI.7 In the past 10 years, 
contemporary and high-sensitivity cardiac troponin assays 
have been developed and adopted in clinical practice. 
They can measure small concentrations of troponin with 
high levels of precision, which means that patients at 
both high and low risk of having an MI could be identi-
fied much earlier in the triage.
Given the large number of cardiac troponin assays 
marketed as ‘high sensitivity’, recent efforts have been 
made to define criteria that could inform policy and clin-
ical decisions. In the development of their guidance on 
early rule out of acute MI,5 the UK’s National Institute for 
Health and Care Excellence (NICE) defined a high-sen-
sitivity cardiac troponin assay as one with a coefficient of 
variation (CV) ≤10% at the 99th centile and an ability to 
measure concentrations in at least 50% of the reference 
population. The systematic review that informed the 
guidance identified only three commercially available 
assays that met the above criteria: the Elecsys Troponin 
T high-sensitive assay (Roche Diagnostics), the ARCHI-
TECTSTAT high-sensitive troponin I (Abbott Labora-
tories) and the AccuTnI+3 (Beckman Coulter).7 More 
recently, the Academy of the American Association for 
Clinical Chemistry and the Task Force on Clinical Appli-
cations of Cardiac Bio-Markers of the International 
Federation of Clinical Chemistry and Laboratory Medi-
cine have endorsed the above definition of high-sensi-
tivity cardiac troponin assay and have recommended ‘that 
assays unable to detect cTn [cardiac troponin] at concen-
trations at or above the LoD [limit of detection] in at least 
50% of healthy men and women be labeled as contempo-
rary cTn [cardiac troponin] assays’. (Wu et al, p6)8
serial testing
Serial measurement of cardiac troponin is employed to 
increase both sensitivity and specificity of the diagnostic 
strategy. This usually involves one sample taken at presen-
tation to the ED and another sample taken one or more 
hours later. The results from these two determinations 
and their difference (‘delta troponin’) are combined 
in a diagnostic rule to determine the likelihood of the 
symptoms being caused by an acute MI. The strategy 
takes advantage of the fact that in the first 24 hours of the 
onset of symptoms, the concentration of cardiac troponin 
in the bloodstream is progressively rising. According to 
the current universal definition, diagnosis of MI requires 
that the patient’s presentation is consistent with cardiac 
ischaemia, cardiac troponin concentration is above the 
99th centile of the reference population and two consec-
utive determinations a few hours apart show a signifi-
cant change (eg, >20%) in cardiac troponin level.9 Such 
patients require urgent reperfusion to restore blood flow 
to the affected part of the heart and should immediately 
be admitted to hospital.
Clinical pathway
Figure 1 shows the clinical pathway for triaging patients 
suspected of MI, including single-sample and two-sample 
cardiac troponin algorithms we identified in our scoping 
searches. Most patients with symptoms suggestive of acute 
coronary syndrome are transported by ambulance or 
present directly to the ED.10 Their initial triage includes 
clinical assessment, medical history and a 12-lead ECG. 
Patients with ST-segment elevation MI (STEMI) or other 
intermediate- or high-risk features are directly admitted 
to hospital. Low-risk patients undergo troponin testing, 
with the first sample taken at presentation and the second 
sample one or more hours later. If both determinations 
are below a prespecified clinical cut-off, for example, 
the 99th centile, and there is no evidence of evolving MI 
(eg, rising troponin, new angina or other symptoms), the 
patient is diagnosed with unstable angina or alternative 
explanation of the symptoms is sought.
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diagnostic strategies used in the triage of patients suspected 
of non-st-segment elevation MI
Taking advantage of the high sensitivity and precision of 
the new generation cardiac troponin assays, a range of 
diagnostic protocols addressing specific clinical scenarios 
have been devised. They could be summarised as follows:
 ► Single-sample protocols to identify patients at low risk 
of MI: If the concentration of troponin in the first 
sample, taken two or more hours after the onset of 
symptoms, is well below the 99th centile (eg, below 
the limit of detection or other prespecified cut-off), 
the probability of MI is also very low and the patient 
could be discharged, if appropriate, or alternative 
explanation of the symptoms could be sought. For 
instance, a meta-analysis conducted by Chapman and 
colleagues11 showed that the negative predictive value 
of Abbott ARCHITECTSTAT high-sensitive cardiac 
troponin I assay (Abbott Laboratories) is 99.5%, 
when the cut-off is ‘<5 ng/L’; the 99th centile of this 
assay is much higher: 34 ng/L for men and 16 ng/L 
for women.12 Alternative early low-risk strategies have 
also been proposed, for example, combining a single-
sample high-sensitivity troponin with copeptin13 14 or 
information from the ECG and risk assessment tools, 
such as the Thrombolysis in Myocardial Infarction 
risk score.15 16 This increases the negative predictive 
value of the protocol and the proportion of patients 
assigned to the low-risk group.
 ► Two-sample protocols to identify patients at low risk 
of MI:
 – If the results from two samples taken one or more 
hours apart are below a prespecified threshold, 
such as the 99th centile or lower, and there is no 
significant change, the probability of MI is low.
 – If both values are slightly above the 99th centile, 
but there is no change, the underlying cause might 
be a chronic condition, such as heart failure or 
myocarditis.
 ► Single-sample protocols to identify patients at high 
risk of MI: In the context of myocardial ischaemia, if 
the concentration of troponin in the first sample is 
well above the 99th centile, the probability of MI is 
high and the patient will most likely be admitted to 
hospital for further testing and treatment.
 ► Two-sample rule-in: The universal diagnosis of MI 
requires that at least one of two consecutive samples 
taken three or more hours apart produces a value 
above the 99th centile, and there is a significant 
change in the concentration of cardiac troponin 
between the first and the second samples.9
The above protocols could be combined in complex 
diagnostic strategies that use different cut-offs to iden-
tify patients at low, intermediate or high risk of MI. Such 
strategies enable clinicians to stratify patients early in the 
triage, so that appropriate referral and treatment deci-
sions could be made without delay.
Figure 1 Clinical pathway for triaging patients suspected of MI, including single-sample and two-sample cardiac troponin 
algorithms identified in scoping searches. MI, myocardial infarction.
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rationale for conducting the review
Recent meta-analyses have focused on single-sample 
protocols designed to identify patients at low risk of 
MI.11 17 18 Such protocols have important implications for 
clinical practice, especially in terms of cost-effectiveness 
and quality of patient care: they could free up capacity 
required for patients who need emergency treatment; 
reduce the number of unnecessary tests and the associ-
ated risks; the focus of clinical investigation could shift 
earlier to an alternative explanation of the patient’s symp-
toms and, if appropriate, the patient could be discharged 
directly from the ED.10
However, single-sample protocols are limited in their 
application, as many patients without MI will present 
with troponin concentrations above the prespecified 
cut-off. Such patients will undergo a second troponin 
determination which, if the inter-sample time is three or 
more hours, as recommended in the current NICE guid-
ance,5 will result in the patients spending many hours in 
hospital. In some cases they will have to stay overnight, 
until a qualified clinician is available to review results and 
make a decision for transfer or discharge.
Various serial testing protocols have been devised and 
validated, including protocols using different cut-offs to 
identify patients at low and high risk of MI and shorter 
(1 or 2 hours) inter-sample time. Such protocols could 
enable discharge or referral decisions to be made for a 
larger proportion of patients while still in the ED. A brief 
scoping of the literature showed considerable variation 
in these protocols and their accuracy, and we can assume 
that the variation in clinical practice is even greater. The 
differences concern the following:
 ► The analytical and diagnostic performance of 
different assays.
 ► The cut-offs used to identify patients at low and high 
risk of MI.
 ► The method of calculating delta troponin: absolute 
versus relative change (eg, >4.5 ng/L vs >20%).
 ► The inter-sample time (one, two or more hours).
Other factors, such as the time from onset of symptoms, 
patient characteristics (eg, age, sex and risk factors) and 
prior tests (eg, ECG findings) are also likely to affect the 
performance of the assays and contribute to the observed 
heterogeneity in study-level estimates.11 This could be 
confusing when making decisions about which protocol 
to implement in practice in order to achieve the best 
balance between accuracy and efficiency (the proportion 
of patients for whom a decision for discharge or admis-
sion to a specialist unit could be made early in the triage).
Therefore, we are proposing to systematically identify, 
review and summarise research evidence pertaining to the 
diagnostic accuracy of contemporary and high-sensitivity 
cardiac troponin assays, when used in serial testing to 
identify MI in symptomatic patients presenting to the ED. 
Our primary objective will be to obtain summary estimates 
of the accuracy of specific protocols and the proportion 
of patients assigned to each risk category. Our secondary 
objectives will be to determine the relative accuracy of 
alternative protocols, including a direct comparison of 
single-sample and two-sample protocols, and to investi-
gate the impact of protocol- and study-level characteris-
tics on test accuracy estimates.
MEthOds And AnAlysIs
In preparing the protocol, we used the Preferred 
Reporting Items for Systematic Reviews and Meta-Analy-
ses-Protocol reporting guidelines.19
Eligibility criteria
Study design
We will include all primary diagnostic accuracy studies 
with single-gate design (also known as diagnostic cohort 
studies). Studies with two-gate design will be excluded 
due to inherent bias in the reported diagnostic accuracy 
estimates.20
Participants
Only studies in patients aged ≥18 years who present to 
the ED with suspicion of acute coronary syndrome will be 
considered for inclusion. Studies in patients with STEMI 
will be excluded, but we will include studies analysing 
jointly STEMI and non-STEMI patients. We will include 
data only for non-STEMI, if such data could be obtained; 
otherwise, we will deal with this in the methodological 
quality assessment and the sensitivity analysis.
Index tests
The index tests are contemporary or high-sensitivity 
cardiac troponin assays used in serial measurement (two 
or more determinations) to identify MI. To qualify as 
‘contemporary’ or ‘high sensitivity’, assays need to have 
CV ≤10% at the 99th percentile of normal; ‘contempo-
rary’ assays should be able to detect cardiac troponin 
in 20% to <50% of healthy individuals and ‘high-sensi-
tivity’ assays in at least 50%. We will include all cardiac 
troponin assays that meet the above criteria. We will ascer-
tain eligibility by checking package inserts of the assays, 
contacting manufacturers and identifying published clin-
ical evaluations.
Target conditions and reference standard
Our primary target condition will be an index diagnosis 
of MI. Our secondary target conditions will be as follow:
 ► A composite outcome of index MI and cardiac death 
within 30 days of the index presentation.
 ► A composite outcome of index MI, death and major 
adverse cardiac events including cardiac arrest, 
emergency revascularisation procedure, cardiogenic 
shock, ventricular arrhythmia or high-degree atrio-
ventricular block requiring intervention, if they occur 
within 30 days of the index presentation.
The reference standard is a final diagnosis of MI adju-
dicated by qualified clinicians according to the universal 
definition of MI.9 The quality of the reference standard, 
such as independence from the index test, adjudication 
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and blinding to the index test results, will be considered 
in the methodological quality assessment.
Outcomes
The main outcomes are test accuracy data reported as 
true positives, false positives, false negatives, and true 
negatives for protocols with dichotomous outcomes, or 
three-by-two tables for protocols that assign patients to 
low-, intermediate- and high-risk categories. If the contin-
gency table is not reported in the paper, we will derive 
data from the sensitivity and specificity estimates, the total 
number of patients and the proportion of those with the 
target condition. Studies that report only test accuracy 
estimates but insufficient detail to reconstruct the orig-
inal contingency table will be included in the review, but 
will be excluded from the quantitative analysis. Studies 
that meet the rest of the criteria, but do not report test 
accuracy data, will be excluded only after we have tried 
but failed to obtain the missing data.
Publication status and language
We will include conference abstracts and unpublished 
studies if they meet our eligibility criteria and we are 
able to obtain the necessary data. We will include all rele-
vant papers regardless of the language in which they are 
published. If necessary, we will arrange translation or data 
extraction by a person fluent in the respective language.
sEArChEs
We plan to perform systematic searches of the following 
electronic databases: MEDLINE (via OvidSp), EMBASE 
(via OvidSP), Science Citation Index (via Web of 
Science), Cochrane Database of Systematic Reviews and 
CENTRAL database (via the Cochrane Library). We will 
search all databases from 1 January 2006 to present, with 
no restrictions on language or publication status. As far 
as we are aware, no studies evaluating the diagnostic 
accuracy of high-sensitivity cardiac troponin assays have 
been published prior to 2010.7 11 17 18 Hence, the choice 
of the above publication date as a cut-off for our searches, 
allowing for some uncertainty in the exact date.
Related systematic reviews will be examined for addi-
tional studies for inclusion. Our search strategy complies 
with the Peer Review of Electronic Search Strategies 2015 
Guideline for developing electronic searches. It was 
developed by an information specialist (MR) with many 
years of experience of using databases for systematic 
reviews, and it combines terms for the target condition, 
index tests and setting. The search strategy for Embase 
is provided as online supplementary appendix 1 in the 
Supplemental file, and the search strategies for the other 
databases could be obtained from the authors on request.
In addition, we will conduct forward and backward 
searches of all included papers and other relevant publi-
cations (eg, previous systematic reviews), and will contact 
experts in the field and study authors to check for missed 
titles or unpublished data.
selection of studies for inclusion
The results from the electronic searches will be imported 
into a reference management software and de-dupli-
cated. Two review authors will conduct all screening 
independently, with disagreements resolved through 
discussion or arbitration. First, we will screen all titles 
and abstracts; the full text of any potentially relevant 
publications will be retrieved and assessed for eligibility 
against our inclusion criteria. The same procedure will be 
repeated for titles identified in the additional searches.
data extraction
We have developed and piloted a data extraction form 
available in the online supplement (online supplemen-
tary appendix 2 in the supplementary file). Data will be 
extracted for the following topics: publication details, 
study characteristics, patients, index tests, reference stan-
dard, outcomes and methodological quality items. Two 
review authors will extract data independently and all 
disagreements will be resolved through discussion or arbi-
tration. Study authors will be contacted for missing data 
and to ascertain the independence of study cohorts, with 
reminders sent 2 weeks after the initial request.
Methodological quality assessment
We will assess the methodological quality of the included 
studies using a tailored version of the Quality Assessment 
of Diagnostic Accuracy Studies version 2 tool. The tool 
consists of four domains: Patient selection, Index test, 
Reference standard and Flow and timing. Each domain 
is assessed for risk of bias and rated as ‘High risk’, ‘Low 
risk’ or ‘Unclear risk’. In addition, the first three domains 
are assessed for applicability concerns and rated using 
the same categories. The authors of the tool recommend 
that it is tailored for each systematic review by adding or 
removing signalling questions.21 A tailored version of the 
tool with details of the signalling questions, operational 
definitions and the rules for combining the answers to 
produce a domain-level rating is included in the Supple-
mentary file (online supplementary appendix 3).
Assessment of publication bias
Given the limited knowledge of publication bias in diag-
nostic accuracy studies and the controversies around 
its assessment,22 23 we will not use statistical methods to 
detect the presence of publication bias. We acknowledge, 
however, that publication bias might be present and have 
bearing on our findings. We will try to mitigate this by 
conducting comprehensive searches of the published 
research, actively seek to identify unpublished data and 
note the possibility of publication bias when reporting 
our findings.
statistical analysis and data synthesis
Contingency tables will be reconstructed from the data 
reported in the papers or by entering sensitivity, spec-
ificity, total number of patients and the proportion of 
those with the target condition in the test accuracy calcu-
lator of the Cochrane Collaboration’s Review Manager 
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5.3 (The Nordic Cochrane Centre, The Cochrane Collab-
oration, 2014). Sensitivity and specificity estimates with 
95% CIs will be calculated and presented in forest plots 
and in the receiver operating characteristics space. Data 
will be grouped by individual assays and protocols. We will 
conduct visual inspection of each plot to determine the 
level and potential sources of heterogeneity and to decide 
whether meta-analysis is appropriate.
For each assay, if a sufficient number of studies per 
protocol are available and the level of clinical and statis-
tical between-study heterogeneity is low, we will conduct 
separate meta-analyses by dichotomising the results from 
studies reporting more than two outcomes (eg, low-, inter-
mediate- and high-risk categories). First, we will combine 
the intermediate- and high-risk categories to obtain 
a two-by-two table for the low-risk rule of the protocol. 
Then, we will combine the low- and intermediate-risk 
categories to obtain a two-by-two table for the high-risk 
rule of the protocol. These will be included in separate 
meta-analyses to obtain summary sensitivity and speci-
ficity for the low-risk and high-risk parts of the protocol.
Since both the index tests and the reference standard 
are cardiac troponin assays for the detection of myocar-
dial necrosis, we assume the presence of incorporation 
bias and will pool the results using the model developed 
by Dendukuri and colleagues.24 The model, an extension 
of the hierarchical summary receiver operating charac-
teristic (HSROC) model, allows correction for imperfect 
reference standard assuming an underlying continuous 
latent variable. The same methods will also be used to 
investigate the comparative accuracy of alternative assays 
and protocols, and the impact of protocol- and study-level 
characteristics. As a sensitivity analysis, we will also analyse 
the data using the HSROC model where incorporation 
bias is not accounted for.
If we decide that pooling of results would be inappro-
priate (for instance, because the number of studies is too 
small and heterogeneity is too great), we will summarise 
the results in tables and graphs, and will provide a narra-
tive summary of the observed differences.
Investigation of heterogeneity
The protocol and study-level characteristics explored will 
include the following potential sources of heterogeneity:
 ► Definition of the target condition: type 1 MI versus 
type 1 and type 2 MI.
 ► Different inter-sample time.
 ► Age (≤65 or >65 years) and sex.
 ► Time since symptom onset (≤2 or >2 hours).
 ► Presence of myocardial ischaemia on ECG, for 
example, ST-segment changes or T-wave inversion.
 ► History of ischaemic heart disease.
sensitivity analysis
If appropriate, we will conduct sensitivity analysis by 
excluding studies of poor methodological quality and the 
most influential studies, to assess the robustness of the 
summary estimates.
EthICs And dIssEMInAtIOn
As this is a systematic review, we are not planning to 
obtain a formal ethical approval. However, we will extract 
and report data on the ethical approval of the included 
studies. The findings from the review will be disseminated 
through publications in peer-reviewed journals, presenta-
tions at conferences and using the websites and networks 
of the two universities. Changes and amendments to the 
protocol will be acknowledged in all presentations and 
publications.
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